• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Officer Le-Nguyen Quoc sold $91,208 worth of shares (15,329 units at $5.95), decreasing direct ownership by 4% to 328,323 units (SEC Form 4)

    4/17/25 4:05:16 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETNB alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Le-Nguyen Quoc

    (Last) (First) (Middle)
    C/O 89BIO, INC.
    655 MONTGOMERY STREET, SUITE 1500

    (Street)
    SAN FRANCISCO CA 94111

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    89bio, Inc. [ ETNB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    04/15/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/15/2025 S(1) 15,329 D $5.95(2) 328,323 D
    Common Stock 14,750 I By Spouse
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on July 1, 2024.
    2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $5.87 to $6.09. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
    Remarks:
    Chief Technical Operations Officer
    /s/ Ryan A. Murr, as attorney-in-fact for Quoc Le-Nguyen 04/17/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ETNB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ETNB

    DatePrice TargetRatingAnalyst
    3/14/2025$11.00Neutral
    Goldman
    3/13/2025$25.00Buy
    Citigroup
    2/4/2025Outperform
    Wolfe Research
    4/22/2024$30.00Buy
    BofA Securities
    1/12/2024$24.00 → $15.00Outperform → Sector Perform
    RBC Capital Mkts
    10/10/2023Outperform → Perform
    Oppenheimer
    8/28/2023$36.00Buy
    UBS
    6/13/2023$49.00Outperform
    Evercore ISI
    More analyst ratings

    $ETNB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 183,885 shares of the Company's common stock to seven new employees (the "Inducement Grants") on May 6, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grants were gran

      5/9/25 4:05:00 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 89bio to Participate in Upcoming Investor Conferences

      SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in the following investor conferences during the month of May: BofA Securities 2025 Health Care ConferenceFormat: Fireside ChatDate: Wednesday, May 14, 2025Time: 1:40 PM ET 2025 RBC Capital Markets Global Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, May 20, 2025Time: 9:30 AM ET The webcast of the fireside chats will be accessible in the invest

      5/6/25 4:05:00 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 89bio Reports First Quarter 2025 Financial Results and Corporate Updates

      – Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) has been fully enrolled and topline data are expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $638.8 million as of March 31, 2025; completed follow-on equity offering in 1Q 2025 with gross proceeds of $287.5 million – SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage

      5/1/25 4:05:00 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETNB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on 89bio with a new price target

      Goldman initiated coverage of 89bio with a rating of Neutral and set a new price target of $11.00

      3/14/25 7:36:30 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on 89bio with a new price target

      Citigroup initiated coverage of 89bio with a rating of Buy and set a new price target of $25.00

      3/13/25 7:35:31 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on 89bio

      Wolfe Research initiated coverage of 89bio with a rating of Outperform

      2/4/25 7:02:09 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETNB
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by 89bio Inc.

      SCHEDULE 13G/A - 89bio, Inc. (0001785173) (Subject)

      5/2/25 5:37:05 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by 89bio Inc.

      10-Q - 89bio, Inc. (0001785173) (Filer)

      5/2/25 4:30:20 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 89bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - 89bio, Inc. (0001785173) (Filer)

      5/1/25 4:05:31 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETNB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $49,999,994 worth of shares (5,714,285 units at $8.75) (SEC Form 4)

      4 - 89bio, Inc. (0001785173) (Issuer)

      2/3/25 5:38:09 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mcwherter Charles bought $99,850 worth of shares (15,000 units at $6.66), increasing direct ownership by 150% to 25,000 units (SEC Form 4)

      4 - 89bio, Inc. (0001785173) (Issuer)

      1/23/25 7:38:31 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Palekar Rohan bought $39,450 worth of shares (5,000 units at $7.89), increasing direct ownership by 1% to 471,236 units (SEC Form 4)

      4 - 89bio, Inc. (0001785173) (Issuer)

      12/10/24 6:02:26 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETNB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ETNB
    Leadership Updates

    Live Leadership Updates

    See more
    • Officer Le-Nguyen Quoc sold $91,208 worth of shares (15,329 units at $5.95), decreasing direct ownership by 4% to 328,323 units (SEC Form 4)

      4 - 89bio, Inc. (0001785173) (Issuer)

      4/17/25 4:05:16 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Le-Nguyen Quoc was granted 14,750 shares and covered exercise/tax liability with 1,050 shares, decreasing direct ownership by 0.30% to 343,652 units (SEC Form 4)

      4 - 89bio, Inc. (0001785173) (Issuer)

      2/19/25 4:01:10 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Martins Ryan covered exercise/tax liability with 780 shares, decreasing direct ownership by 0.29% to 269,674 units (SEC Form 4)

      4 - 89bio, Inc. (0001785173) (Issuer)

      2/19/25 4:01:07 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

      SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the Company. "We are delighted to welcome Dr. Teresa Perney to our executive leadership team at this critical juncture for 89bio," said Rohan Palekar, CEO of 89bio. "As we advance pegozafermin through

      9/16/24 4:05:00 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 89bio Appoints Francis Sarena as Chief Operating Officer

      SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena as Chief Operating Officer, effective August 5, 2024. "We are excited to welcome Francis to our executive team at this pivotal growth phase for 89bio," said Rohan Palekar, CEO of 89bio. "As we advance our Phase 3 clinical program for pegozafermin and prepare for scale up, Francis' extensive strategic, operational, business development and leadership expertise will be immensely valuable. His prov

      8/7/24 8:00:00 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

      SAN FRANCISCO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Dr. Charles McWherter to its Board of Directors, effective July 30, 2024. Dr. McWherter most recently served as Chief Scientific Officer and President of Research and Development of CymaBay Therapeutics until it was acquired by Gilead Sciences in March 2024. "We are thrilled to welcome Charles, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, CEO of 89bio. "His expertise in drug dev

      8/5/24 8:00:00 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETNB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by 89bio Inc.

      SC 13D/A - 89bio, Inc. (0001785173) (Subject)

      11/18/24 8:19:11 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by 89bio Inc.

      SC 13G/A - 89bio, Inc. (0001785173) (Subject)

      11/14/24 4:30:44 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by 89bio Inc.

      SC 13G/A - 89bio, Inc. (0001785173) (Subject)

      11/14/24 12:47:48 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ETNB
    Financials

    Live finance-specific insights

    See more
    • 89bio's Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks

      - 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH resolution without worsening of fibrosis (p=0.0005) - - 30mg QW dose had a placebo-adjusted effect size of 19% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 21% on NASH resolution without worsening of fibrosis (p=0.0009) - - 44mg Q2W and 30mg QW doses had at least one-stage fibrosis improvement without worsening of NASH at 3.5 times placebo rate and NASH resolution without worsening of fibrosis at 12 to 14 times placebo rate - - Every-two-week dose data reinforces pegozafermin's pot

      3/22/23 7:00:00 AM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

      - Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on background therapy - - Observed significant and potent reductions in atherogenic lipids (non-HDL-C and apo B), liver fat, and improvements in liver enzymes and glycemic control markers - - ENTRIGUE results support 89bio's transition to a late-stage development company; Phase 3 expected to initiate in first half of 2023 - - Conference call and webcast today at 1:30 p.m. PST/4:30 p.m. EST - SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, In

      6/28/22 4:01:00 PM ET
      $ETNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update

      - Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 – - $142.5 million in cash and cash equivalents expected to provide runway into the second half of 2023 – - Appointment of Rohan Palekar to Board of Directors – - Company to host conference call today, March 1, 2022 at 1:30 p.m. PT / 4:30 p.m. ET – SEATTLE, March 01, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the year ended December 31, 2021.

      3/1/22 4:03:00 PM ET
      $ETNB
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care